Evidence-Based Oncology | Peer Exchange: Oncology Stakeholders Summit

Evidence-Based Oncology

The American Society of Clinical Oncology (ASCO)’s Value Framework evaluates the clinical benefit, toxicity, and cost of new interventions compared with the standard of care. ASCO’s CMO, Richard Schilsky, MD, FACP, FASCO, explains their plans to make the framework useful for clinical decisions at the point of care.
Peter Bach, MD, MAPP, director, Center for Health and Policy Research, Memorial Sloan Kettering Cancer Center, speaks about DrugAbacus, the importance of using value frameworks, and using the European market as a model to recalibrate the healthcare system in the United States.
Measuring the quality of oncology care and associating it with reimbursement, and high drug prices remain important concerns of value-based outpatient cancer care. A healthcare economist reviews the current status and suggests a potential path forward.
In this interview, Steven D. Pearson, MD, MSc, FRCP, founder and president of the Institute for Clinical and Economic Review, talks about the various value tools that have been developed, the need for understanding the budgetary impact of healthcare costs, and why stakeholders are interested in innovative models such as indication-based pricing.
A review of the various value calculators that have emerged to measure the value of cancer therapies—these calculators reflect the interests of their developers and vary substantially in their intention, format, and usability.

More issues

Compendia
Clinical Pathways Compendium
COPD Compendium
Diabetes Compendium
GI Compendium
Lipids Compendium
MACRA Compendium
Oncology Compendium
Rare Disease Compendium
Reimbursement Compendium
Know Your News
HF Compendium
$vacMongoViewPlus$